LMNB2 couples USP37-dependent MYC stabilization to glycolytic flux in gastric cancer and is actionable with ZIF-8–delivered siRNA
This study identifies LMNB2 as a critical oncogenic driver in gastric cancer that stabilizes MYC via USP37 to promote glycolytic flux, and demonstrates that pH-responsive ZIF-8 nanoparticles delivering LMNB2 siRNA effectively suppress tumor progression by targeting this metabolic axis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Gastric cancer, a disease that begins in the lining of the stomach, remains one of the most dangerous and difficult-to-treat cancers in the world. A major reason for its deadliness is how quickly it grows and spreads, a process fueled by a specific way cancer cells consume energy. Unlike healthy cells that burn fuel efficiently, these cancer cells often switch to a rapid, less efficient method called glycolysis, which allows them to multiply at breakneck speeds. This metabolic shift is driven by a powerful protein called MYC, which acts like a master switch, turning on the genes that help the cell eat sugar and grow. However, scientists have long struggled to understand exactly what keeps the MYC protein stable and active in the stomach, and how to stop it without harming the patient.
A team of researchers has now uncovered a hidden chain of events that explains how a specific protein helps gastric cancer cells thrive. They discovered that a protein named LMNB2, which normally helps hold the nucleus of a cell together, is found in unusually high amounts in stomach tumors. The researchers found that this excess LMNB2 does not just sit there; it actively recruits another protein called USP37. This partnership works like a protective shield for the MYC protein. Normally, cells have a built-in recycling system that breaks down proteins when they are no longer needed, but the LMNB2 and USP37 team prevents MYC from being recycled. By keeping MYC levels high and stable, the cancer cell is able to turn on its sugar-burning machinery, fueling its rapid growth and ability to spread to other parts of the body.
To prove this connection, the scientists examined tissue samples from 128 patients who had undergone surgery for stomach cancer. They found that patients with high levels of LMNB2 had more advanced tumors and a lower chance of survival compared to those with lower levels. In the lab, when the researchers reduced the amount of LMNB2 in cancer cells, the cells stopped growing as fast, lost their ability to move and invade other tissues, and their sugar consumption dropped significantly. The study showed that without LMNB2, the protective shield around MYC collapsed, leading to the rapid breakdown of the MYC protein and a slowdown in the cancer's energy production. This confirmed that LMNB2 is a critical driver of the disease, acting through a specific pathway involving USP37 to keep the cancer fueled.
The researchers also tackled the difficult challenge of how to stop this process in a living body. Simply trying to block the protein with drugs is often difficult because the body breaks down treatments before they reach the tumor. To solve this, the team designed a tiny delivery vehicle made from a material called ZIF-8, which is a porous, sponge-like structure made of zinc and organic molecules. They loaded this vehicle with a special genetic tool called siRNA, which is designed to silence the LMNB2 gene. This vehicle is smart: it remains stable in the normal, neutral environment of the blood but begins to break apart and release its cargo when it encounters the acidic environment inside a tumor.
When tested in mice with stomach tumors, these tiny vehicles traveled to the cancer sites and held their position for up to 48 hours, whereas free genetic material disappeared quickly. Once inside the tumor, the vehicles released the siRNA, which successfully turned off the LMNB2 gene. The result was a dramatic reduction in tumor size and weight, along with a significant decrease in the cancer's ability to spread to the lungs. The treatment worked by dismantling the protective shield around MYC, causing the cancer cells to lose their energy advantage and stop dividing.
This work offers a new perspective on how stomach cancer survives and a potential new way to fight it. By identifying LMNB2 as a key player that stabilizes the cancer's growth engine, the study provides a clear target for therapy. The success of the ZIF-8 delivery system suggests that it may be possible to deliver genetic treatments directly to tumors with high precision, avoiding the damage to healthy tissue that often comes with traditional chemotherapy. While the researchers note that more testing is needed to ensure long-term safety and effectiveness in humans, their findings provide a compelling roadmap for disrupting the metabolic fuel supply of gastric cancer and potentially improving outcomes for patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.